PHG Stock Analysis: Buy, Sell, or Hold?
PHG - KONINKLIJKE PHILIPS N.V.
$27.29
-0.11 (-0.40%)
▼
5d:
-0.55%
30d:
-10.05%
90d:
-0.37%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When PHG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHG trading at deep discount. Market pricing in -4.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PHG trading at deep discount. Market pricing in -4.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$48.99
Based on 9.3% avg growth
INTRINSIC VALUE TODAY
$30.42
10.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHG is currently trading at $27.29, which is considered oversold relative to its 30-day fair value range of $27.53 to $31.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.1) compared to its historical average (15.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHG is in a uptrend. The price is approaching resistance at $27.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+25.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHG is in a uptrend. The price is approaching resistance at $27.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+25.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$27.53 -
$31.23
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.9% below Wall St target ($34.35)
Fair Price Analysis
30-Day Fair Range
$27.53 -
$31.23
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$26.07
Resistance Level
$27.66
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.08
Wall Street Target
$34.35
(+25.9%)
Revenue Growth (YoY)
1.1%
Earnings Growth (YoY)
-0.5%
Profit Margin
5.0%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
13.1 vs 15.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$26.01
(-5%)
2-Year Target
$24.79
(-9%)
3-Year Target
$23.62
(-13%)
3-Yr Target (if PE normalizes)
(PE: 13→15)
$27.26
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 14.6%)
$70.23
(+157%)
Base:
(SPY PE: 13.1, Growth: 14.6%)
$41.11
(+51%)
Bear:
(PE: 11.1, Growth: 14.6%)
$34.94
(+28%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 24.53 | Current EPS (TTM): $1.07
Bull Case
$56.48
(+111%)
Analyst growth 95.6%, PE expands to 27.0
Base Case
$51.34
(+92%)
Market implied 95.6%, PE stable at 24.5
Bear Case
$17.85
(-33%)
Severe decline -20.0%, PE contracts to 20.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.1 to 15.1
Stabilization Target:
$31.50
(+15.4%)
PE Expansion Potential:
+15.4%
Share & Embed Analysis
Last updated: April 02, 2026 3:57 AM ET
Data refreshes hourly during market hours. Next update: 4:57 AM
Data refreshes hourly during market hours. Next update: 4:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 61 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 54 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
